Mitochondrial dynamics and quality control are crucial for neuronal survival and their perturbation is a major cause of neurodegeneration. m-AAA complex is an ATP-dependent metalloprotease located in the inner mitochondrial membrane and involved in protein quality control. Mutations in the m-AAA subunits AFG3L2 and paraplegin are associated with autosomal dominant spinocerebellar ataxia (SCA28) and autosomal recessive hereditary spastic paraplegia (SPG7), respectively.
INTRODUCTION
The mitochondrial matrix AAA metalloprotease (m-AAA) is an ATPdependent proteolytic complex located in the inner mitochondrial membrane (IMM), where it carries out protein quality control by degrading nonassembled or damaged proteins of the IMM and participates in the processing and maturation of some mitochondrial proteins (Esser, Tursun, Ingenhoven, Michaelis, & Pratje, 2002; Koppen & Langer, 2007; Nolden et al., 2005) . In humans, m-AAA exists in two different subunit compositions: a heterocomplex composed of AFG3L2 and paraplegin and a homocomplex constituted of AFG3L2 only. Interestingly, mutations in AFG3L2 (MIM# 604581) cause an autosomal dominant form of spinocerebellar ataxia (SCA28, MIM# 610246; Di Bella et al., 2010) , while loss-of-function mutations in SPG7 (encoding paraplegin, MIM# 602783) cause an autosomal recessive form of hereditary spastic paraplegia (SPG7, MIM# 607259; Casari et al., 1998) . Furthermore, homozygous hypomorphic AFG3L2 mutations have been associated with a complex autosomal recessive spastic ataxia syndrome (SPAX5, MIM# 614487; Muona et al., 2015; Pierson et al., 2011) , while dominant mutations of SPG7 (Klebe et al., 2012) and AFG3L2 (Charif et al., 2015) have been associated with nonsyndromic dominant optic atrophy (DOA).
We report here co-occurrence of a heterozygous de novo AFG3L2 missense mutation (p.R468C) and a maternally inherited heterozygous intragenic deletion of SPG7 in a patient with a complex ataxic and extrapyramidal phenotype with early-onset optic atrophy. Interestingly, the AFG3L2 p.R468C mutation was recently reported in a dominant family with optic atrophy and mild intellectual disability (Charif et al., 2015) and in a sporadic patient with isolated optic atrophy (Colavito et al., 2017) . In neither case did the patients manifest ataxia, spasticity, or extrapyramidal involvement. Thus, the clinical and cellular studies described here suggest that co-occurrence of AFG3L2 and SPG7 mutations may result in a new complex phenotype not attributable to either of the two genes individually.
MATERIALS AND METHODS

Patient and DNA samples
All procedures involving human subjects were approved by the Institutional Review Board of the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, in agreement with the Declaration of Helsinki.
Each individual providing a biological sample signed written informed consent approved by the Institutional Review Board of the Foundation IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, in agreement with the Declaration of Helsinki. Genomic DNA was prepared from peripheral-blood lymphocytes using standard procedures as previously described (Gellera et al., 2007) .
Genetic studies
Mutation screening of AFG3L2, SPG7, and OPA1 (MIM# 605290) genes was performed by Sanger sequencing, while copy number variation of SPG7 was detected by MLPA (Multiplex Ligation-dependent Probe Amplification, MRC-Holland, Amsterdam, The Netherlands).
Sequences of the oligonucleotide primers are available upon request.
DNA mutation numbering system is based on cDNA sequence.
Nucleotides are numbered so that the first nucleotide of the first inframe ATG codon in the reference sequence is nucleotide +1. Amino acids are numbered so that methionine encoded by the first in-frame ATG codon in the reference sequence is Met1.
Segregation study was performed using an ultra-deep (≥20,000×) sequencing of PCR amplicons. NGS library was prepared from PCR amplicons using Nextera XT DNA Library Preparation Kit (Illumina, Inc., San Diego, CA) according to the manufacturer's instructions and sequenced on a MiSeq sequencing apparatus (Illumina, Inc.) with high depth of coverage (>20,000-fold) for mosaicism detection.
Paternity testing was performed using multiallelic variable number of tandem repeat (VNTR) polymorphisms 3 ′ APOB-VNTR (Deka et al., 1992) and D11S533 (Eubanks, Selleri, Hart, Rosette, & Evans, 1991 (Richards et al., 2015) . Potentially pathogenic variants in genes associated with optic atrophy, dystonia, spastic paraplegia, ataxia, or Parkinson disease (Supporting Information Tables S1 and S2) were confirmed in the proband by Sanger sequencing and segregated in her parents by Illumina Nextera XT deep sequencing.
AFG3L2 and paraplegin yeast expression plasmids
Plasmids for heterologous expression of human AFG3L2 and paraplegin in yeast were generated as previously described (Di Bella et al., 2010) . Mutations were introduced into the yeast construct pYC6/CTADH1-AFG3L2-V5/HIS using the QuikChange XL SiteDirected Mutagenesis Kit (Stratagene-Agilent, Cedar Creek, TX).
All AFG3L2 forms were C-ter tagged with the V5 epitope (amino acid residues 95-108, GKPIPNPLLGLDST, of RNA polymerase alpha subunit of simian virus 5). Sequences of oligonucleotide primers used for site-directed mutagenesis are available upon request. Plasmid pYC2/CT-ADH1-AFG3L2-myc carrying wild-type (WT) AFG3L2 was used to express AFG3L2 mut /AFG3L2 wt complex as previously described (Di Bella et al., 2010) . Plasmid YCplac111ADH1-Yta10(1-63)-paraplegin(59-795)-HA was used to express human paraplegin as previously described (Di Bella et al., 2010) .
Yeast strains and growth conditions
All strains used in this study (Supporting Information Table S3 ) derived from W303 (K699, MATa ho ade2-1 trp1-1 can1-100 leu2-3,12 his3-11,15 ura3 ssd1) . A double-knockout yeast strain (yta10Δyta12Δ) was generated by deleting YTA10 and YTA12, the yeast orthologs of human AFG3L2 and paraplegin, respectively, using the one-step PCR system; the obtained strain was transformed as previously described (Di Bella et al., 2010) . Cells were grown at 28 • C on YEP medium (1%-yeast extract, 2%-peptone, 2%-agar for plates) or selective medium supplemented with 2% (w/v) glucose according to standard procedures.
Blasticidin-resistant transformants were selected on YEP medium supplemented with 50 g of blasticidin S per milliliter. For complementation experiments, equal amounts of fivefold serial dilutions of cells from exponentially grown cultures were spotted onto YEP plates containing 2% (w/v) glucose (YPD) or 2% (w/v) glycerol (YPG) and incubated at 28 • C or 37 • C, as indicated. For growth rate analysis, we precultured overnight yeast cells in selective medium supplemented with 2% (w/v) galactose and 0.1% (w/v) glucose and then cultured them in YEP medium supplemented with 2% (w/v) glycerol for 24 hr, inoculated at a standard density of approximately 1 × 10 6 cells/ml.
We removed samples at 0, 20, and 24 hr and determined cell density spectrophotometrically, expressed as OD 600 . For western blot analysis, yeast cells were cultured overnight in selective medium supplemented with 2% (w/v) galactose and 0.1% (w/v) glucose and normalized spectrophotometrically at OD 600 .
Immunoblot analysis and antibodies
For western blot analysis of yeast cells, trichloroacetic acid protein extracts were prepared as described (Muzi-Falconi et al., 1993 Yeast cell mitochondria were prepared by differential centrifugations. The resulting mitochondrial pellet was resuspended in 10 mM potassium phosphate buffer and freezed and thawed for three times.
Assays of respiratory chain complexes activity
Protein concentration was determined by Bradford microplate microassay (Bio-Rad Laboratories, Hercules, CA) with bovine serum albumin as the standard. Respiratory chain enzyme activities were determined spectrophotometrically as previously described (Di Bella et al., 2010; Magri et al., 2010) . Activity was expressed as nanomoles per minute per milligram of protein.
Co-immunoprecipitation of AFG3L2 and paraplegin
For immunoprecipitation experiments, yeast cells were precultured overnight in a selective medium and then grown in 100 ml of YPD medium until 1 × 10 7 cell/ml as previously described (Fracasso, Lazzaro, & Muzi-Falconi, 2010 
Patient-derived cell lines
Epstein-Barr-virus-stabilized lymphoblastoid cell lines (LCLs) from patients, their relatives, and control subjects were established and cultured as previously described (Gellera et al., 2007) . Fibroblasts from patient and controls were grown in the DMEM-high glucose or -galactose media as described previously (Wong et al., 1999) . 
Analysis of mitochondrial morphology
Gene expression analysis
Total RNA was isolated from fibroblast cell lines derived from the 
RESULTS
Case report
The proband is a 25-year-old woman with negative family history.
She has nonconsanguineous healthy parents and two unaffected twin brothers ( Figure 1a ). The disease presented at the age of 5 years with severe visual impairment (bilateral 1/20 visual acuity) and signs of primary optic atrophy: reduction of optic disc size with mild diffuse pallor, wedge-shaped area of excavation of the temporal sector, and normal retinal blood vessels. At the age of 6 years, the patient manifested a slowly progressive motor impairment characterized by bradykinesia, internal rotation of right foot, and gait and balance instability. At 10 years, brain magnetic resonance imaging (MRI), visual 
Genetic analysis
Functional analysis of AFG3L2 p.R468C variant in yeast
The functional consequences of AFG3L2 p.R468C variant were assessed using the yeast model we previously described (Di Bella et al., 2010 Figure S4a ) and in a persistent deficiency of both proteolytic and dislocase (ATPase) activities (Supporting Information Figure S4b and c, respectively). Altogether, these experiments demonstrate the pathogenicity of the p.R468C variant and suggest that it functionally inactivates both homo-and heterocomplex likely via a dominant-negative mechanism (Veitia, Caburet, & Birchler, 2018) .
Enzyme activity assay of respiratory chain complexes III, IV, and V in AFG3L2 R468C cells showed a reduction of >80% as compared to AFG3L2 WT (Figure 2c) . Notably, in comparison with the SCA28 mutations, the p.R468C is associated with a more severe Cox reduction (>90%) that persisted unchanged upon coexpression of paraplegin, consistent with the dominant effect of this mutation.
Immunoblot protein level quantitation showed a severe reduction of both mitochondria-encoded Cox subunits (Cox1p, Cox2p, and Cox3p) and nucleus-encoded subunit Cox4p indicating a general downregulation of the whole enzyme (Supporting Information Figure S5 ).
We also evaluated residual activity of human mutated m-AAA complexes, measuring the processing of the two known substrates of yeast m-AAA: the ROS-scavenger protein Ccp1 (Esser et al., 2002 ) and the ribosomal subunit MrpL32 (Nolden et al., 2005) . In particular, the Remarkably, the severity of the AFG3L2 p.R468C mutation is also demonstrated by the impairment of its own maturation that physiologically occurs by autocatalytic processing (Koppen, Bonn, Ehses, & Langer, 2009 (Ogura, Whiteheart, & Wilkinson, 2004) . Coordinated ATP hydrolysis within the AAA ring of m-AAA proteases has been proposed to increase the efficiency of the proteolytic machine (Augustin et al., 2009) , likely by inducing conformational changes necessary for protease functioning (Suno et al., 2006) . It is conceivable that the dynamic motion of the subunits may differ between the homo-and heterocomplex, making the latter more vulnerable to the presence of a mutation in the crucial ATP sensor 468 residue.
To investigate the ability of AFG3L2 R468C to assemble in a heterocomplex, we performed co-immunoprecipitation in strains coexpressing paraplegin and AFG3L2 WT or AFG3L2 R468C (Supporting Figure S7 ), which showed that AFG3L2 R468C is able to interact with paraplegin in its precursor form (lane 6).
Altogether, coexpression studies, substrate processing experiments, and co-immunoprecipitation results demonstrate that AFG3L2 R468C mutant can assemble into both homomeric (AFG3L2/A FG3L2) and heteromeric (AFG3L2/paraplegin) complexes that are substantially inactive.
Functional analysis in patient's cells
To investigate the effect of m-AAA impairment on human cellular phenotype, we studied fibroblasts and LCLs derived from the patient and controls. First, immunoquantitation in the patient's cells showed normal levels of AFG3L2 but reduced levels of paraplegin, consistent with heterozygosity for the SPG7 null mutation (Supporting Information Figure S8a ). We then analyzed the processing pattern of MRPL32
and OPA1, a dynamin-related protein (DRP1) crucial for mitochondrial dynamics and cristae morphogenesis and responsible for most (Figure 4a ). In particular, we observed a reduction of the long form L2 and the short form S2, and an accumulation of the S3 form. The same OPA1 pattern alteration was observed also in patient's LCLs (Supporting Information Figure S8a ).
Since under various stress conditions (loss of membrane potential, heat stress, reduction of ATP level, Bax/Bak aggregation, and other mitochondrial stress conditions), the cleavage of OPA1 long forms is enhanced by the overactivation of OMA1, an inducible ATPindependent metalloprotease of the IMM (Baker et al., 2014; Quirós et al., 2012) , we investigated whether an increase in OMA1 mRNA could be implicated in the aberrant processing pattern of OPA1 observed in the patient's cells (Supporting Information Figure S10 ).
We did not detect any statistically significant difference between OMA1 mRNA levels in patient's and controls' cells, which indicates that OMA1-increased activity, if any, is not mediated by transcriptional activation.
Since a balance of short and long OPA1 forms is required for mitochondrial fusion activity in mammals (Song, Chen, Fiket, Alexander, & Chan, 2007) , we investigated the morphology of the mitochondrial network. Analysis by confocal microscopy revealed a significant fragmentation in patient's fibroblasts as compared to control cells (Figure 4b and c) . Consistently, analysis of AR and F (Koopman et al., 2006) , which describe mitochondrial shape (length) and branching, respectively, showed significantly lower values in patient's cells than in control cells (Figure 4c ). However, despite this mitochondrial fragmentation, oxygen consumption rate (determined using Seahorse Bioscience XF Cell Mito Stress Test) was similar in patient's and controls'
fibroblasts (data not shown). Notably, this is consistent with the recent observation that energetic competence of the cell may be independent of mitochondrial network morphology (Del Dotto et al., 2017) .
DISCUSSION
In the present study, we describe for the first time a patient carrying heterozygous mutations in the AFG3L2 and SPG7 genes that encode the subunits of the mitochondrial m-AAA protease: AFG3L2:p.R468C
(de novo) and SPG7:p.Glu127SerfsTer2 (maternally inherited). This genotype is associated with a severe complex phenotype characterized by early-onset optic atrophy, L-dopa-responsive syndromic parkinsonism with abnormal dopaminergic uptake in the basal ganglia on SPECT/DaT scan (Figure 1b) , spastic ataxia, and mild cognitive impairment. An extensive sequence analysis of the known genes causing optic atrophy, Parkinson disease, and hereditary dystonia allowed to exclude other molecular causes for the observed phenotype. Interestingly, the AFG3L2 mutation p.R468C was recently described in a family with DOA and mild intellectual disability without any sign of ataxia, spasticity, or extrapyramidal involvement (Charif et al., 2015) and in a sporadic patient with isolated optic atrophy (Colavito et al., 2017) .
Although it was dominantly inherited in the first family, its transmission pattern could not be established in the second case. Interestingly, the de novo nature of the mutation in our patient ( Figure 1a and Supporting Information Figure S3 ) clearly indicates that AFG3L2 NM_006796.2:c.1402C is a mutational hotspot.
The phenotype-genotype comparison between our AFG3L2/SPG7 patient and the patients with AFG3L2 p.R468C only (Charif et al., 2015; Colavito et al., 2017) suggests that the early-onset optic atrophy phenotype is due to this particular AFG3L2 mutation, whose effects are greatly aggravated in our patient by the concurrent defect of paraplegin. Unlike AFG3L2 mutations causing SCA28, which predominantly affect the proteolytic domain (Cagnoli et al., 2010; Di Bella et al., 2010) , the p.R468C mutation involves a highly conserved arginine of the SRH region of the ATPase domain. The corresponding arginine of various AAA/AAA+ ATPases is essential for ATP hydrolysis because it acts as a sensor for the presence of ATP in the neighbor subunit interacting with the ATP -phosphate in the ATP-binding pocket of the adjacent subunit (Ogura et al., 2004) . Thus, this residue represents the arginine finger that contributes to the coupling of the free energy of ATP hydrolysis to the conformational changes necessary to drive the translocation of a substrate polypeptide to the protease catalytic sites (Suno et al., 2006) .
Consistently, functional analysis in our yeast model demonstrated that p.R468C completely abolished both the ATPase-dependent dislocase activity, essential for the processing of membrane proteins (Figure 3b ), and the proteolytic competence (Figure 3a) . Interestingly, we demonstrated that in yeast AFG3L2 R468C retains the ability to assemble in complexes (Supporting Information Figure S7 ) but is unable to support its autoprocessing and the proteolytic activation of paraplegin (Figure 3c and d) , which would indicate that the complex is inactive. By contrast, the SCA28 mutations (p.E691K and p.S674L; Di Bella et al., 2010 ) that affect the proteolytic domain not only modestly alter the ATP-dependent dislocase activity (these AFG3L2 mutants are able to process Ccp1 almost as AFG3L2 WT does; Figure 3b ), but also show a residual proteolytic activity (Figure 3a, c, and d by reduced cage activity, loss of balance, and frank uncoordinated gait with dystonic movements of the head by 9 weeks of age. Later, they lost significant weight, became cachexic, and eventually died within the 4th month of life (Martinelli et al., 2009) . Therefore, these mice displayed an acceleration of the features of paraplegin-deficient mice (Ferreirinha et al., 2004) , showing axonal degeneration in the spinal cord much earlier (13 weeks vs. 8 months) than in the sole absence of Spg7. Altogether, these findings suggest that neurons are very sensitive to the global levels and the subunit composition of m-AAA proteases and lend support to the hypothesis that digenic inheritance of AFG3L2 and SPG7 mutations may result in more complex phenotype(s) not attributable to either of the two genes individually.
Another striking difference from SCA28 patients (Cagnoli et al., 2006; Di Bella et al., 2010) gene (Carelli et al., 2015; Lynch et al., 2017) . OPA1 is a dynamin-like
GTPase that regulates the critical balance between fusion and fission in the dynamic mitochondrial network (MacVicar & Langer, 2016) .
Fission (division of a single organelle into two or more independent structures) and the opposing reaction (fusion) are the main processes for adapting mitochondrial morphology to metabolic changes and cellular needs (Lee & Yoon, 2016) . They are governed by DRP1 for fission and by mitofusins (MFN1 and MFN2) and OPA1 for fusion of the outer mitochondrial membrane and inner membrane, respectively.
OPA1 exists in eight different forms generated by alternative splicing and protease cleavage, which are usually seen as five bands in gels: two long forms (L1 and L2) and three short forms (S1-S3; Ishihara, Fujita, Oka, & Mihara, 2006) . Because balance between long (profusion) and short (profission) forms is required for the maintenance of mitochondrial morphology and fitness, OPA1 processing involves several mitochondrial proteases and is differentially regulated under stress conditions MacVicar & Langer, 2016; Song et al., 2007) . Interestingly, in the patient's cells, we observed a reduction of the long fusogenic OPA1 forms and an accumulation of the shortest ones that promote mitochondrial fission (Figure 4b ). Consistently, we observed fragmentation of the mitochondrial network, which was present neither in SCA28 cells (Figure 4c and d ; Supporting Information Figure S9 ) nor in SPG7 (paraplegin-deficient) cells (Pfeffer et al., 2014) . Richter, Lahtinen, Marttinen, Suomi, and Battersby (2015) proposed that the loss of m-AAA may lead to overaccumulation of de novo mito-synthesized proteins in the IMM, which in turn would cause mitochondrial membrane potential dissipation and activation of the OMA1 metalloprotease that processes the long OPA1 isoforms to the shortest ones. However, we could not detect any significant alteration of OMA1 mRNA in the patient's cells (Supporting Information Figure S10 ), which suggests that activation, if any, of OMA1 occurs at the protein level, as previously proposed (Baker et al., 2014; Bohovych, Donaldson, Christianson, Zahayko, & Khalimonchuk, 2014; Consolato, Maltecca, Tulli, Sambri, & Casari, 2018; Head, Griparic, Amiri, Gandre-Babbe, & van der Bliek, 2009 ). We can therefore hypothesize that the simultaneous occurrence of an AFG3L2
dominant-negative mutation in the crucial ATP sensor and a halved dose of its companion paraplegin may alter both quantitatively and qualitatively the subunit composition and availability of m-AAA complexes to such extent as to severely impair mitochondria fitness with deficiency of respiratory chain complex I and abnormal OPA1 processing by the stress-activated OMA1 protease, detectable also in nonneuronal cell lines. Furthermore, as expression data indicate that the levels of each subunit of the m-AAA protease are very different in distinct subsets of neurons (Di Bella et al., 2010; Martinelli et al., 2009) , it is conceivable that a combined defect of both subunits might cause neuronal dysfunction distinct from that occurring in AFG3L2-associated SCA28 or paraplegin-associated SPG7, thus accounting for the peculiar phenotype observed in the patient reported here.
In conclusion, this study suggests that co-occurring mutations in both components of the mitochondrial m-AAA proteases may cause a novel m-AAA-pathy with a crucial pathogenic role of OPA1. These results would also widen the repertoire of disease genes causing earlyonset parkinsonism and strengthen the crucial role of mitochondrial dysfunction-and in particular of mitochondrial dynamics and protein quality control-in a growing spectrum of neurodegenerative phenotypes. However, further experiments aimed at rescuing the cell phenotype and/or evidence for further cases with a similar genotype will be required for confirming that concurrent alterations of both components of the m-AAA complex are responsible for such a distinct cellular and clinical phenotype.
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